Powel Brown
M.D. Anderson Cancer Center · University of Texas (UT) MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Powel Brown as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:11 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT03382574 · Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-OophorectomyNational Cancer Institute (NCI) · terminated · Ovarian Carcinoma · principal investigator
- Ph1/Ph2NCT01021215 · Zileuton With or Without Celecoxib As Chemopreventive Agents in SmokersNational Cancer Institute (NCI) · completed · Tobacco Use Disorder · principal investigator
- N/ANCT00555152 · Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In SituNational Cancer Institute (NCI) · completed · Ductal Breast Carcinoma In Situ, HER2/Neu Positive · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- 28 Cancer PreventionP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2023 · $18,707 awarded in 2023Grant number is on one of their registry trials
- OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH26120120003 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2014 to 2023 · $183,238 awarded in 2023Same name and institution; not confirmed by an ID
- iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial ConsortiumUG1CA242609 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2022 · $911,328 awarded in 2022Same name and institution; not confirmed by an ID
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers-- Targeting the PARP Pathway for the Prevention of Breast Cancer75N91019D00 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2022 · $1,121,090 awarded in 2022Same name and institution; not confirmed by an ID
- IGF::OT::IGF DETERMINATION OF DOSING REGIMENS OF ERLOTINIB IN COMBINATION WITH SULINDAC FOR PREVENTION OF COLORECTAL CANCER WHILE REDUCING AGENT TOXICITY POP 06/01/2017 - 05/31/201926120150001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2015 to 2019 · $204,459 awarded in 2019Same name and institution; not confirmed by an ID
- International Conference on Novel Strategies to Prevent Cancer by Targeting Infection, Inflammation, and the Immune SystemR13CA243568 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 · $20,000 awarded in 2019Same name and institution; not confirmed by an ID
- 10th International ICAPS Conference 2016 on Lung Cancer Prevention with a Consensus Conference on Early Detection and Prevention of Lung CancerR13CA213968 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2016 · $20,000 awarded in 2016Same name and institution; not confirmed by an ID
- Combination Chemoprevention: Prevention of Both ER-Positive & ER-Negative BCP50CA058183 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2008 to 2012 · $224,390 awarded in 2012Grant number is on one of their registry trials
- Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive AgentsN01CN35159- · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2011 · $1,681,697 awarded in 2011Grant number is on one of their registry trials
- Targeting AP-1 / ER Crosstalk for the Prevention and Treatment of Breast CancerR01CA123246 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2007 to 2011 · $291,194 awarded in 2011Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:11 UTC. The ranking covers the 200 most relevant of 368 PubMed records, and a shared surname and initials can bring in a namesake. All 368 on PubMed
- A randomized trial of bevacizumab for newly diagnosed glioblastoma.N Engl J Med · 20142,246 citationsRCR 69.8
- 1,410 citationsRCR 55.2
- 989 citationsRCR 38.2
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.N Engl J Med · 2016803 citationsRCR 29.8
- Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.Neuro Oncol · 2013729 citationsRCR 22.7
- Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.J Clin Oncol · 2020700 citationsRCR 35.2
- 658 citationsRCR 18.9
- Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.Lancet Oncol · 2017640 citationsRCR 24.3
- 524 citationsRCR 11.6
- Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.J Clin Oncol · 2012488 citationsRCR 13.7